Azacitadine (AZA)

DRUG3 trials

Sponsors

Stelexis BioSciences, Institute of Hematology & Blood Diseases Hospital, China, Janssen Research & Development, LLC

Conditions

AMLAML, AdultFLT3 Gene MutationLeukemia, Myeloid, AcuteMDSMyelodysplastic Neoplasms

Phase 1

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS

RecruitingNCT06533761

Stelexis BioSciencesAML, Adult, MDS

Start: 2025-04-28End: 2028-09-15Target: 105Updated: 2026-10-20

The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

RecruitingNCT06561880

Institute of Hematology & Blood Diseases Hospital, ChinaAML, FLT3 Gene Mutation

Start: 2024-10-08End: 2027-08-31Target: 66Updated: 2026-05-13

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Active, not recruitingNCT06651229

Janssen Research & Development, LLCLeukemia, Myeloid, Acute, Myelodysplastic Neoplasms

Start: 2025-03-21End: 2028-02-09Updated: 2026-09-28

Related Papers

Safety and efficacy of eganelisib in adults with higher-risk myelodysplastic syndrome (HR-MDS) or relapsed/refractory (R/R) acute myeloid leukemia (AML).

Journal of Clinical Oncology2026-05-27

A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib As Monotherapy and in Combination with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood2024-11-05